Clinical TrialMay 14, 2026, 07:36 AM
Incannex Healthcare Commences DReAMzz Clinical Study for IHL-42X
AI Summary
Incannex Healthcare Inc. announced the official commencement of its DReAMzz clinical study evaluating IHL-42X for the treatment of obstructive sleep apnea (OSA). This marks a significant operational and strategic milestone, with all 14 clinical trial sites identified, drug product manufacturing completed, and necessary permits secured. The DReAMzz study is designed to optimize IHL-42X's dosing profile and strengthen the design of the planned Phase III development program, building on positive Phase II data and FDA Fast Track designation.
Key Highlights
- Incannex Healthcare officially commenced its DReAMzz clinical study for IHL-42X in obstructive sleep apnea (OSA).
- All 14 clinical trial sites have been identified, and trial infrastructure is activated.
- Manufacturing of IHL-42X drug product is complete, with import/export permits secured.
- A global distribution partner has been onboarded to support supply chain management.
- The DReAMzz study is a crossover dose optimization study to refine IHL-42X's dosing profile.
- The study aims to strengthen and de-risk the planned Phase III development program.
- IHL-42X previously received U.S. FDA Fast Track designation for OSA treatment.
Price Impact
More from IXHL